Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-23
2007-10-23
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S143000
Reexamination Certificate
active
10505358
ABSTRACT:
The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5and R6are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilizing them
REFERENCES:
patent: 4045439 (1977-08-01), Preston et al.
patent: 5508288 (1996-04-01), Forbes et al.
patent: 2003/0158188 (2003-08-01), Chih-Hung Lee et al.
patent: 2003/0158198 (2003-08-01), Chih-Hung Lee et al.
patent: 583207 (1933-08-01), None
patent: 1157626 (1963-11-01), None
patent: 2502588 (1976-07-01), None
patent: WO93/18028 (1993-09-01), None
patent: WO9324458 (1993-12-01), None
patent: WO9414801 (1994-07-01), None
patent: WO 0026203 (2000-05-01), None
patent: WO 028221 (2002-01-01), None
patent: WO 03014064 (2003-02-01), None
patent: WO 03/070247 (2003-08-01), None
Nowak et al, Studies in Organic Chemistry, vol. 35, 1988, pp. 438-440.
Enamine Product Listing,2002:280319, Chemcats, (Nov. 15, 2001).
Scientific Exchange Product List,2003:2364305, Chemcats, (Jan. 1, 2003).
Shiv K. Agarwal, et al.,Indian Journal of Chemistry, vol. 31B, pp. 177-182, (Mar. 1992).
Teruki Honma, et al.,Journal of Medicinal Chemistry, American Chemical Society, vol. 44, pp. 4615-4627, (2001).
Henryka Poradowska, et al.,Roczniki Chemii Annales Societatis Chimicae Polonorum, vol. 49, pp. 1577-1580, (1975).
Henryka Poradowska, et al.,Polish Journal of Chemistry—Polish Chemical Society, vol. 53, pp. 1895-1900, (1979).
J. H. Musser, et al.,Journal of Medicinal Chemistry, American Chemical Society, vol. 30, No. 1, pp. 62-67, (1987).
K. C. Joshi, et al.,Journal of the Indian Chemical Society, The Indian Chemical Society, vol. 54, pp. 1104-1105, (1977).
S. M. Sondhi, et al.,Monatshefte Fur Chemie Chemical Monthly, vol. 131, No. 5, pp. 511-520, (2000).
Jewoo Lee, et al.,Bioorganic&Medicinal Chemistry, vol. 9, pp. 1713-1720, (2001).
Communication pursuant to Article 96(2) EPC dated Oct. 20, 2006.
Letter from Merck & Co., Inc to European Patent Office dated Dec. 9, 2005.
Brown Rebecca Elizabeth
Doughty Victoria Alexandra
Hollingworth Gregory John
Jones A. Brian
Lindon Matthew John
Davis Zinna N.
Krovatin William
Rubin David
LandOfFree
Heteroaromatic urea derivatives as VR-1 receptor modulators... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaromatic urea derivatives as VR-1 receptor modulators..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaromatic urea derivatives as VR-1 receptor modulators... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823396